Vfend tablets, 50mg and 200mg had US sales of $81 million while Vfend oral suspension, 40 mg/mL had US sales of $15.2 million
Lupin has launched its Voriconazole tablets, 50 mg and 200 mg and Voriconazole oral suspension, 40 mg/mL having received an approval from the United States Food and Drug Administration (FDA) earlier to market a generic equivalent of PF Prism CV’s Vfend tablets, 50 mg and 200 mg and Vfend oral suspension, 40 mg/mL.
Voriconazole tablets, 50 mg and 200 mg and Voriconazole oral suspension, 40 mg/mL are the AB rated generic equivalent of PF Prism CV’s Vfend tablets, 50 mg and 200 mg and Vfend oral suspension, 40 mg/mL.
It is indicated for use in patients 12 years of age and older in the treatment of the following fungal infections:
Invasive Aspergillosis
Candidemia in non-neutropenic patients and the following candida infections
Disseminated infections in skin and infections in abdomen, kidney, bladder wall and wounds
Esophageal Candidiasis
Serious fungal infections caused by Scedosporium apiospermum (Asexual form of Pseudallescheria boydii) and Fusarium spp. including Fusarium solani in patients intolerant of or refractory to other therapy
Vfend tablets, 50mg and 200mg had US sales of $81 million while Vfend oral suspension, 40 mg/mL had US sales of $15.2 million.
Comments are closed.